Claims for Patent: 7,906,137

Summary for Patent: 7,906,137

Title:	Delivery agents for enhancing mucosal absorption of therapeutic agents
Abstract:	A delivery agent for delivering a biologically active agent to a warm-blooded animal includes a hydrophobic moiety covalently bonded to a hydrophilic moiety. The hydrophobic moiety can include bile acids, sterols, or hydrophobic small molecules. The hydrophilic moiety can include .alpha.-amino acids, dipeptides or tripeptides, or hydrophilic small molecules. An illustrative delivery agent is N.sup..alpha.-deoxycholyl-L-lysine-methylester. The delivery agent and the biologically active agent are mixed together to form a complex, which is then administered to the animal. These complexes are particularly useful for oral administration of biologically active agents, but other routes of administration may be used.
Inventor(s):	Byun; Youngro (Kwangju, KR), Lee; Seulki (Seoul, KR), Moon; Hyuntae (Kwangju, KR)
Assignee:	Mediplex Corporation, Korea (Samsung-Dong, Kangnam-Ku, Seoul, KR)
Application Number:	10/851,477
Patent Claims:	1. A composition comprising a mixture of a biologically active agent and a delivery agent, wherein the delivery agent comprises (a) a hydrophobic moiety selected from the group consisting of cholic acid, deoxycholic acid, chenodeoxycholic acid, lithocholic acid, ursocholic acid, ursodeoxycholic acid, isoursodeoxycholic acid, lagodeoxycholic acid, glycocholic acid, taurocholic acid, glycodeoxycholic acid, glycochenodeoxycholic acid, dehydrocholic acid, hyocholic acid, hyodeoxycholic acid, and mixtures thereof and (b) N.sup..alpha.-L-lysine-methylester covalently bonded to the hydrophobic moiety. 2. The composition of claim 1 wherein the composition comprises a reversible complex that is decomplexed in the blood stream after delivery to a warm-blooded animal. 3. The composition of claim 1 wherein the biologically active agent comprises insulin. 4. The composition of claim 1 wherein the hydrophobic moiety comprises deoxycholic acid. 5. The composition of claim 1 wherein the delivery agent has a molecular weight of about 400 to about 4000 daltons. 6. The composition of claim 1 further comprising one or more members selected from the group consisting of excipients, diluents, disintegrants, lubricants, plasticizers, colorants, and mixtures thereof. 7. A dosage form for delivery of a biologically active agent to a warm-blooded animal, the dosage form comprising a mixture of the biologically active agent and a delivery agent, wherein the delivery agent comprises (a) a hydrophobic moiety selected from the group consisting of bile acids, sterols, and small hydrophobic molecules having a molecular weight of less than about 500 daltons and (b) N.sup..alpha.-L-lysine-methylester covalently bonded to the hydrophobic moiety; wherein the biologically active agent is selected from the group consisting of human growth hormone, recombinant human growth hormone, bovine growth hormone, porcine growth hormone, growth hormone-releasing hormone, alpha-interferon, beta-interferon, gamma-interferon, interleukin-1, interleukin-2, insulin, porcine insulin, bovine insulin, human insulin, human recombinant insulin, insulin-like growth factor (IGF), insulin-like growth factor-1 (IGF-1), glucagon-like peptide-1 (GLP-1), heparin, unfractionated heparin, heparinoids, dermatans, chondroitins, low molecular weight heparin, pentasaccharide, calcitonin, salmon calcitonin, eel calcitonin, human calcitonin, erythropoietin, atrial naturetic factor, antigens, monoclonal antibodies, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, leutinizing-hormone-releasing-hormone, follicle stimulating hormone, glucocerebrosidase, thromboprotein, fugrastim, prostaglandins, cyclosporin, vasopressin, cromolyn sodium, sodium chromoglycate, disodium chromoglycate, vancomycin, parathyroid hormone, fragments of parathyroid hormone, desferrioxamine, and vitamins; analogs, fragments, mimetics, and polyethylene glycol-modified derivatives thereof; and mixtures thereof. 8. The dosage form of claim 7 further comprising one or more members selected from the group consisting of excipients, diluents, disintegrants, lubricants, plasticizers, colorants, and mixtures thereof. 9. The dosage form of claim 7 wherein the hydrophobic moiety comprises deoxycholic acid. 10. The dosage form of claim 7 wherein the delivery agent has a molecular weight of about 400 to about 4000 daltons. 11. The dosage form of claim 7 wherein the dosage form comprises a tablet, a capsule, a powder, a liquid, or an emulsion.

Details for Patent 7,906,137

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	10/28/1982		2039-03-29
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	12/29/2015		2039-03-29
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	08/06/1998		2039-03-29
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	03/31/1994		2039-03-29